Li Mengtao

Specializes in the standardized diagnosis and treatment of various rheumatic diseases, particularly scleroderma, dermatomyositis, and pulmonary hypertension. Received his Doctor of Medicine degree from Peking Union Medical College (8-year program) in 1999. He participated in an exchange program at the University of California, San Francisco School of Medicine, and was among the first batch of staff selected for the hospital's "Hundred Talents Program" to visit and exchange ideas at six rheumatology centers in the United States. He also received "Healthcare Leadership" training at the Mayo Clinic for middle-level management. He has worked at Peking Union Medical College Hospital since 1999 and was appointed Dr./Chief Physician and Doctoral Supervisor in the Department of Rheumatology and Immunology in 2012. He has been continuously awarded titles such as Excellent Resident Physician, Excellent Chief Resident Physician, Excellent Attending Physician, Excellent Diagnostics Teacher, Excellent Internship Supervisor, and Excellent Clinical Teaching Dr.. He is also a university-level Excellent Teacher and a model of educational innovation by the Beijing Municipal Education Union.

Currently serving as the Chairman of the Rheumatology Branch of the Beijing Medical Association, Vice Chairman of the Rheumatology Branch of the Chinese Medical Association, Vice President and Head of the Pulmonary Vascular/Interstitial Disease Group of the Rheumatology and Immunology Physicians Branch of the Chinese Medical Doctor Association, Standing Committee Member and Deputy Secretary-General of the Immunoadsorption Academic Committee of the Chinese Medical Doctor Association, Member of the Cardiac Critical Care Expert Committee of the Critical Care Medicine Physicians Branch of the Chinese Medical Doctor Association, Member of the Systemic Lupus Erythematosus Study Group of the Asia-Pacific League Against Rheumatism (APLAR), and Member of the Asia-Pacific Systemic Lupus Erythematosus Collaborative Group (APLC). His main research areas include the clinical diagnosis and treatment of complex rheumatic diseases, especially pulmonary hypertension related to connective tissue diseases, as well as registration cohorts and applied basic research. As a core member, he participates in the organization and implementation of the Chinese Systemic Lupus Erythematosus Research Collaborative Group (CSTAR), the National Rheumatology Data Center (CRDC), the China Rheumatology and Immunology Medical Consortium (CRCA), and the National Clinical Research Center for Skin and Immune Diseases (NCRC-DID). As the principal investigator, I have undertaken the 13th Five-Year Plan key research and development project "Clinical Cohort and Prognostic Study of Systemic Lupus Erythematosus" and the Capital Collaborative Innovation Key Project "Randomized Controlled Clinical Intervention Study of Innovative Drugs for Systemic Lupus Erythematosus". My team has presented at 30 international conferences and published 60 SCI articles as first/corresponding author. I have received the Outstanding Research Award from the Chinese Rheumatology Society, the Young Investigator Award from the East Asian Rheumatology Congress (EAGOR), the Young Clinical Investigator Award from the Asia-Pacific League Against Rheumatism (APLAR), and the Travel Award from the European League Against Rheumatism (EULAR).